Specialty Pharma Journal Specialty, Precision & Technology
SAN DIEGO and PENNINGTON, N.J, Dec. 12, 2018 /PRNewswire/ — OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing novel cancer immunotherapies, today announced an update regarding tumor responses in its KEYNOTE-695 global, multicenter Phase 2b, open-label trial of intratumoral delivery of TAVO™ (tavokinogene telseplasmid / IL-12) with intravenous KEYTRUDA® …
Tag Archives: melanoma
December, 2018
November, 2018
-
20 November
Genentech to Pay $100 Million to Immunocore to Co-Develop Investigational Drug Targeting Tumors Expressing MAGE-A4
(Oxford, UK and Conshohocken, US, 19 November 2018) Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company focused on delivering first-in-class biological therapies that have the potential to transform lives of people with serious diseases, today announces it has entered into a new partnership with Genentech, a member of …
-
9 November
New Data Support Ongoing Clinical Program for Lenvima and Keytruda Combination Across Multiple Tumor Types
TOKYO & KENILWORTH, N.J.–(BUSINESS WIRE)–Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from presentations of new data and analyses of LENVIMA® (lenvatinib), an orally available kinase inhibitor discovered by Eisai, in combination with Merck’s anti-PD-1 …
-
7 November
OncoSec Reports Preliminary Data from Phase 2b Trial of Tavo in Combination with Keytruda in Patients with Metastatic Melanoma
SAN DIEGO and PENNINGTON, N.J., Nov. 6, 2018 /PRNewswire/ — OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing novel cancer immunotherapies based on its proprietary technology generating sustained intratumoral IL-12 levels, today reported preliminary data from KEYNOTE-695, a global, multicenter Phase 2b, open-label trial of intratumoral delivery of TAVO™ (tavokinogene telseplasmid / IL-12) with intravenous …
October, 2018
-
30 October
Study Demonstrates DecisionDx-Melanoma Prognostic Test Accuracy in Patients with Stage II-IIIA Melanoma
FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced the presentation of data highlighting how the accuracy of the DecisionDx®-Melanoma gene expression profile (GEP) test in patients with Stage II and IIIA melanoma can improve adjuvant clinical trial design …
August, 2018
-
2 August
Castle Biosciences’ DecisionDx-Melanoma Test Improved AJCC-Based Risk Prediction for Melanoma Recurrence and Metastasis
FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer treatment decisions, today announced the presentation of new data showing that the DecisionDx®-Melanoma test improved risk prediction beyond that using American Joint Committee on Cancer (AJCC) based staging. The study was presented at the …
June, 2018
-
28 June
FDA Approves Array BioPharma’s Baftovi in Combination with Mektovi for Treatment of Metastatic Melanoma
BOULDER, Colo., June 27, 2018 /PRNewswire/ — Array BioPharma Inc. (Nasdaq: ARRY) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI™ capsules in combination with MEKTOVI® tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, as detected by an FDA-approved test. BRAFTOVI is not indicated for the treatment of patients with wild-type BRAF melanoma. …
-
5 June
Opdivo Demonstrates Sustained, Superior Recurrence-Free Survival Versus Yervoy in Late-Stage Melanoma Trial
PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced updated results from the Phase 3 CheckMate -238 trial evaluating Opdivo (nivolumab) versus Yervoy (ipilimumab) in patients with stage IIIB/C or stage IV melanoma who are at high risk of recurrence following complete surgical resection. In updated results from the study, Opdivo continued to demonstrate statistically longer recurrence-free survival (RFS) of …
-
5 June
Array Announces Additional Median Overall Survival Results of Encorafenib and Binimetinib in Patients with Braf-Mutant Advanced Melanoma
BOULDER, Colo., June 4, 2018 /PRNewswire/ — Array BioPharma Inc. (NASDAQ: ARRY) today announced updated results from the Phase 3 COLUMBUS trial in BRAF-mutant advanced melanoma. The results showed median overall survival (mOS) was 33.6 months for patients treated with the combination of encorafenib and binimetinib compared to 16.9 months for patients treated with vemurafenib as …
May, 2018
-
31 May
Syndax and Nektar Therapeutics Partner for Immuno-Oncology Clinical Trial
WALTHAM, Mass. and SAN FRANCISCO, May 30, 2018 /PRNewswire/ — Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, and Nektar Therapeutics (Nasdaq: NKTR) today announced a non-exclusive, clinical collaboration to evaluate the safety and efficacy of Nektar’s NKTR-214, a CD122-biased agonist, …